Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689233 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
A Phase 3 study of Alzheimers Disease, sponsored by TauRx Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 20
- Study locations
NCT01689233: Completed Phase 3 study of Alzheimers Disease, sponsored by TauRx Therapeutics.
NCT01689233 is a Phase 3 study of Alzheimers Disease that has completed, run by TauRx Therapeutics. The registered enrollment target is 800 participants, below the 4,056-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01689233, a Phase 3 study of Alzheimers Disease, has completed, sponsored by TauRx Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TRx0237 200 mg/day
Study Locations (20)
California
- CITrials - Bellflower
- ATP Clinical Research, Inc. - Costa Mesa
- Southern California Research, LLC - Fountain Valley
- Feldman, Robert MD - Laguna Hills
- Synergy East - Lemon Grove
- Collaborative Neuroscience Network - Long Beach
- Neuro-Therapeutics, Inc. - Pasadena
- Anderson Clinical Research - Redlands
- Pacific Research Network - San Diego
- San Francisco Clinical Research Center - San Francisco
- Neurological Research Institute - Santa Monica
- Schuster Medical Research Institute - Sherman Oaks
Connecticut
- Institute for Neurodegenerative Disorders - New Haven
- Coastal Connecticut Research, LLC - New London
- Research Center for Clinical Studies, Inc - Norwalk
Arizona
- Xenoscience, Inc / 21st Century Neurology - Phoenix
- NoesisPharma Clinical Trials - Phoenix
Florida
- JEM Research - Atlantis
- Bradenton Research Center - Bradenton
Colorado
- Mile High Research Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01689233
The ClinicalTrials.gov registry entry for NCT01689233 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,056-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (80% lower). The listed sponsor is TauRx Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01689233 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Connecticut, Arizona.
Frequently Asked Questions
What is clinical trial NCT01689233 about?
NCT01689233 is a clinical study titled "Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease". The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.
What is the current status of trial NCT01689233?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2012-10. Estimated completion is 2016-05.
What conditions does trial NCT01689233 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01689233?
The interventions under investigation include: Placebo (DRUG), TRx0237 200 mg/day (DRUG).
Who is sponsoring clinical trial NCT01689233?
This trial is sponsored by TauRx Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01689233 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
ACTIVE NOT RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.